Cowen raised its price target on Mylan (NASDAQ: MYL) to $36.00 (from $30.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Momenta Phama (MNTA) Declines to Comment on Status of Generic Capoxone 40mg - BloombergOctober 4, 2017 9:53 AM Pre-Open Stock Movers 10/04: (CTMX) (CATB) (MYL) Higher; (CLSN) (MNTA) (TEVA) (ODP) Lower (more...)October 4, 2017 9:30 AM Teva Pharma (TEVA) Says it Remains Confident in Patient and Physician Loyalty to COPAXONEOctober 4, 2017 9:28 AM Mylan Provides Support for U.S. Disaster-Relief EffortsOctober 4, 2017 8:00 AM Wall St. extends run of record highs; services data upbeatOctober 4, 2017 7:54 AM Mylan (MYL): Raising PT On Copaxone Approval - Wells FargoOctober 4, 2017 7:46 AM Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic ApprovalOctober 4, 2017 7:27 AM Mylan's (MYL) Surprise Copaxone Generic Approval 'Quite Negative' for Teva Pharma (TEVA) - MizuhoOctober 4, 2017 7:02 AM Mylan (MYL): A Big Win - BMOOctober 4, 2017 6:55 AM Momenta Phama (MNTA) on Watch After Mylan (MYL) Granted FDA Approval of First Generic for CopaxoneOctober 4, 2017 6:42 AM Teva Pharma (TEVA) volatility flat into Mylan (MYL) granted FDA approval of CopaxoneOctober 4, 2017 6:20 AM Mylan (MYL) volatility flat into announces FDA approval of ANDAs for Glatiramer Acetate Injection October 4, 2017 6:16 AM Teva (TEVA) Shares Pressured After Mylan (MYL) Granted FDA Approval of First Generic for CopaxoneOctober 4, 2017 6:14 AM Mylan (MYL) Granted FDA Approval of First Generic for CopaxoneOctober 4, 2017 5:49 AM Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day ExclusivityOctober 3, 2017 9:58 PM U.S. House committee launches probe of Allergan patent dealOctober 3, 2017 1:02 PM Mylan (MYL) Announces Launch of Generic Cancidas for InjectionOctober 2, 2017 12:40 PM Mylan Launches Generic Cancidas® for InjectionOctober 2, 2017 12:40 PM